Tenascin C (TNC) (EGF Like Domain) Antikörper

Antigen: Tenascin C (TNC)

Synonyme: TN, HXB, MGC167029, Hxb, Ten, TN-C, AI528729, MGC144208, MGC144209, cytotactin, tenascin-C, C130033P17Rik, tenc, wu:fk04d02, TNC, tn, MGC140517

Epitope: EGF Like Domain

Klonalität: Monoklonal (4F10TT)

Wirt: Maus

Reaktivität: Human

Applikation: Immunhistochemie (IHC), Western Blot (WB)

Produktnummer: ABIN180063

Produktbeschreibung

Weitere Bezeichnung: Tenascin-C (EGF Like Domain)

Immunogen: Purified human glioma tenascin-C

Isotyp: IgG1  (Passende Sekundärantikörper)

Klon: 4F10TT

Beschreibung: Tenascin-C (TN-C) is a component of the extracellular matrix (ECM) that has been shown to be involved in tissue interactions during fetal development and oncogenesis. It is glycoprotein consisting of six disulphide monomer isoforms being generated by alternative splicing. A high molecular weight variant that is generated by alternative splicing of RNAs of TN-C was found predominantly in breast, prostatic and colorectal cancers. The appearance of such a large TN-C isoform has been suggested to be of significance for tumour progression. The function of the variant in tumors has been worthy of remark (Reference No.5). This monoclonal antibody can specifically be recognized EGF like domain of TN-C, therefore the antibody can be detected in all TN-C isoforms.

Spezifität: Specifically reacts with EGF like domain of all TN-C variants. Cross-reacts with Mouse, Rat, Chicken and Rabbit

Anwendungen

Applikationshinweise: This antibody can be stained in formalin fixed paraffin embedded tissues with trypsin pretreatment by several immunohistochemical techniques such as Avidin Biotin Complex (ABC) Method. The optimal dilution is about 5 ug/ml, however, the dilution rate should be optimized by each laboratories. This antibody can be used for western blotting in concentration of about 1 ug /ml.

Reinigung: Protein A

Buffer: Lyophilized product from 1% BSA in PBS containing 0.05%NaN3 . Reconstitution: 1.0 ml distilled water will be added to the product, then the concentration comes to 100 ug/ml

Lagerung: Lyophilized product, 5 years at 2 ­ 8 : Solution, 2 years at ­20

Forschungsgebiet: Krebs, Extrazelluläre Matrix

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

Human Breast Cancer

anti-Tenascin C (TNC) (EGF Like Domain) antibody (Image 2)

Publikationen

Publikationen: Tamaoki, Imanaka-Yoshida, Yokoyama et al.: "Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury." in: The American journal of pathology, Vol. 167, Issue 1, pp. 71-80, 2005 (PubMed).

Mekonnen, Ijzer, Nederbragt: "Tenascin-C in chronic canine hepatitis: immunohistochemical localization and correlation with necro-inflammatory activity, fibrotic stage, and expression of alpha-smooth muscle actin, cytokeratin 7, and CD3+ cells." in: Veterinary pathology, Vol. 44, Issue 6, pp. 803-13, 2007 (PubMed).

Nakoshi, Hasegawa, Sudo et al.: "Regulation of tenascin-C expression by tumor necrosis factor-alpha in cultured human osteoarthritis chondrocytes." in: The Journal of rheumatology, Vol. 35, Issue 1, pp. 147-52, 2008 (PubMed).

Tsukada, Terasaki, Shimomura et al.: "High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation." in: Human pathology, Vol. 40, Issue 7, pp. 1015-22, 2009 (PubMed).